NextCure, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and advancing novel immunomedicines to treat cancer patients who do not respond to, or have disease progression on, current therapies. The company's core products include therapeutic candidates such as LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4 for the treatment of multiple solid tumors; NC410, a fusion protein of LAIR-2 designed to block immune suppression mediated by LAIR-1 and showing clinical activity in colorectal and ovarian cancers; and NC525, a monoclonal antibody targeting LAIR-1 focused on treating acute myeloid leukemia (AML) blast cells and leukemic stem cells. NextCure also pursues preclinical oncology and non-oncology programs leveraging its proprietary FIND-IOTM platform that identifies novel immune-oncology targets and biomarkers to develop therapies modulating immune responses in the tumor microenvironment. The company operates primarily in the United States from its headquarters in Beltsville, Maryland, and focuses on patients with cancer types inadequately addressed by existing therapies. Recent major developments include a strategic reprioritization in 2024 to advance the LNCB74 ADC program, with completion of the first cohort of a Phase 1 trial in early 2025 and plans to initiate backfill cohorts in the second half of the year. In 2025, NextCure formed a strategic partnership with Simcere Zaiming to advance a Phase 1 ADC program, SIM0505 (CDH6 ADC), acquiring global rights outside greater China and dosing the first U.S. patient in October 2025. The company successfully closed a private placement PIPE financing in November 2025, raising approximately $21.5 million to support its operational and clinical trial activities. NextCure aims to deliver proof-of-concept data for its key ADC programs, including LNCB74 and SIM0505, by the first half of 2026. The company continues to leverage its expertise in immune biology, antibody-drug conjugates, and biomarker-driven development as a strategy to address high unmet medical needs in oncology. Founded in 2015, NextCure maintains a focused pipeline predominantly in oncology immunotherapy and operates with around 40 employees. Its business segments include clinical oncology programs such as NC410, NC525, and LNCB74, combined with preclinical efforts targeting the tumor microenvironment and immune modulation. NextCure’s innovative approach integrates novel mechanisms of action, including immune checkpoint modulation and antibody-drug conjugates, to enhance immune response against cancer. The company remains committed to advancing its pipeline and strategic collaborations to expand its therapeutic offerings on a global scale.
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer